Therapeutic Area: Other Immune Biology
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J, et al.
Blood
January 2022
Authors and Affiliates
Jesus San-Miguel,1 Herve Avet-Loiseau, 2 Bruno Paiva,1 Shaji Kumar,3 Meletios A. Dimopoulos,4 Thierry Facon,5 Marıa-Victoria Mateos, 6Cyrille Touzeau,7 Andrzej Jakubowiak,8 Saad Z. Usmani,9 Gordon Cook,10 Michele Cavo,11 Hang Quach,12 Jon Ukropec,13 Priya Ramaswami,14 Huiling Pei,14 Mia Qi,15 Steven Sun,15 Jianping Wang,15 Maria Krevvata,16 Nikki DeAngelis,16 Christoph Heuck,16 Rian Van Rampelbergh,17 Anupa Kudva,15 Rachel Kobos,15 Ming Qi,16 and Nizar J. Bahlis,18
1Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain; 2Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France; 3Department of Hematology, Mayo Clinic, Rochester,MN; 4National and Kapodistrian University of Athens, Athens, Greece; 5University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 6University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 7Hematology, University Hospital Hotel-Dieu, Nantes, France; 8University of Chicago Medical Center, Chicago, IL; 9Levine Cancer Institute/Atrium Health, Charlotte, NC; 10Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; 11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli, ” Universita di Bologna, Bologna, Italy; 12University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC; 13Janssen Global Medical Affairs, Horsham, PA; 14Janssen Research & Development, LLC, Titusville, NJ; 15Janssen Research & Development, LLC, Raritan, NJ; 16Janssen Research & Development, LLC, Spring House, PA; 17Janssen Research & Development, Beerse, Belgium; and 18Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
DJ‐1 depletion prevents immunoaging in T‐cell compartments
Authors and Affiliates
Ni Zeng 1,2, Christophe M Capelle 1,2, Alexandre Baron 1, Takumi Kobayashi 1, Severine Cire 1, Vera Tslaf 1,2,3, Cathy Leonard 1, Djalil Coowar 4, Haruhiko Koseki 5,6, Astrid M Westendorf 7, Jan Buer 7, Dirk Brenner 1,4, Rejko Krüger 3,4,8, Rudi Balling 4, Markus Ollert 1,9, Feng Q Hefeng 1,7;
1 Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
2 Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
3 Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
4 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg.
5 Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
6 AMED-CREST, Japanese Agency for Medical Research and Development, Yokohama, Japan.
7 Institute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
8 Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg.
9 Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.
Positive and negative selection shape the human naïve B cell repertoire
Authors and Affiliates
Jeff W Chen 1, Jean-Nicolas Schickel 1, Nikolaos Tsakiris 1, Joel Sng 1, Florent Arbogast 1, Delphine Bouis 1, Daniele Parisi 1, Ruchi Gera 1, Joshua M Boeckers 1, Fabien R Delmotte 1, Margaret Veselits 2, Catharina Schuetz 3, Eva-Maria Jacobsen 3, Carsten Posovszky 3, Ansgar S Schulz 3, Klaus Schwarz 3, Marcus R Clark 2, Laurence Menard 1, Eric Meffre 1;
1 Department of Immunobiology, Yale University, New Haven, United States of America.
2 Department of Medicine, University of Chicago, Chicago, United States of America.
3 Department of Pediatrics and Adolescent Medicine, Ulm University, Ulm, Germany.
Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells.
Wong SW, et al.
Frontiers in Oncology
December 2021
Authors and Affiliates
Sandy W. Wong1, Nina Shah1, Guy Ledergor 1, Thomas Martin1, Jeffrey Wolf 1 ,Amy M. Shui 2, Chiung-Yu Huang2 and Joaquin Martinez-Lopez 1,3
1 Bone Marrow Transplantation and Hematologic Malignancy Unit, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, United States, 2 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States, 3 Hospital Universitario 12 de Octubre, Complutense University, Centro Nacional de investigacion en Oncolgia (CNIO), i+12, CIBER de oncologia (CIBERONC), Madrid, Spain
Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P, et al.
Clinical Chemistry
November 2021
Authors and Affiliates
Pieter Langerhorst,a, Somayya Noori ,b, Marina Zajec,b,c Yolanda B. De Rijke,c Jolein Gloerich,a Alain J. van Gool,a He´le`ne Caillon,d Irma Joosten,a Theo M. Luider,b Jill Corre,e Martijn M. VanDuijn,b, Thomas Dejoie,d, and Joannes F.M. Jacobsa
aDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; bDepartment of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands; cDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands; dLaboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France; eUnite de Genomique du Myelome, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S, et al.
American Cancer Society Cancer
November 2021
Authors and Affiliates
Sagar Lonial, MD 1; Hans C. Lee, MD2; Ashraf Badros, MD 3; Suzanne Trudel, MD4; Ajay K. Nooka, MD 1; Ajai Chari, MD 5; Al-Ola Abdallah, MD6; Natalie Callander, MD7; Douglas Sborov, MD8; Attaya Suvannasankha, MD9; Katja Weisel, MD10; Peter M. Voorhees, MD11; Lynsey Womersley, MSc12; January Baron, MS13; Trisha Piontek, BSN13; Eric Lewis, MD14; Joanna Opalinska, MD13; Ira Gupta, MD13; and Adam D. Cohen, MD15
1Winship Cancer Institute, Emory University, Atlanta, Georgia; 2Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas; 3Greenebaum Cancer Center, Bone Marrow Transplant Program, University of Maryland at Baltimore, Baltimore, Maryland; 4Princess Margaret Cancer Center, Toronto, Ontario, Canada; 5Icahn School of Medicine at Mount Sinai, New York, New York; 6University of Kansas Cancer Center, Fairway, Kansas; 7Carbone Cancer
Center, University of Wisconsin, Madison, Wisconsin; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; 9Indiana University Cancer Center, Indianapolis, Indiana; 10Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany; 11Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; 12GlaxoSmithKline, Stockley Park, United Kingdom; 13GlaxoSmithKline, Upper Providence, Pennsylvania; 14GlaxoSmithKline, Research Triangle Park, North Carolina; 15Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ, et al.
Journal of Clinical Oncology
November 2021
Authors and Affiliates
Luciano J. Costa, MD, PhD1,2; Saurabh Chhabra, MD3; Eva Medvedova, MD4; Bhagirathbhai R. Dholaria, MD5; Timothy M. Schmidt, MD6; Kelly N. Godby, MD1,2; Rebecca Silbermann, MD4; Binod Dhakal, MD3; Susan Bal, MD1,2; Smith Giri, MD1,2; Anita D’Souza, MD3; Aric Hall, MD6; Pamela Hardwick, RN2; James Omel, MD7; Robert F. Cornell, MD5; Parameswaran Hari, MD3; and Natalie S. Callander, MD6
1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL 2O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL 3Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 4Oregon Health & Science University, Portland, OR 5Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 6University of Wisconsin, Madison, WI 7Independent Patient Advocate, Omaha, NE
An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission
Biavat L, et al.
November 2021
Authors and Affiliates
Luca Biavati 1, Carol Ann Huff 2, Anna Ferguson 3, Amy Sidorski 4, M Amanda Stevens 5, Lakshmi Rudraraju 6, Cristina Zucchinetti 1, Syed Abbas Ali 2, Philip Imus 1, Christian B Gocke 2, Rachel M Gittelman 7, Sarah Johnson 8, Catherine Sanders 9, Marissa Vignali 10, Anita Gandhi 11, Xiaobu Ye 3, Kimberly A Noonan 6, Ivan Borrello 12;
1 Oncology, Johns Hopkins Medicine.
2 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine.
3 Oncology, Johns Hopkins University.
4 Johns Hopkins University School of Medicine.
5 Hematologic Malignancies, Johns Hopkins Medicine.
6 Johns Hopkins Medicine.
7 Adaptive Biotechnologies (United States).
8 Computational Biology, Adaptive Biotechnologies (United States).
9 Business Development, Adaptive Biotechnologies (United States).
10 Adaptive Biotechnology.
11 Bristol-Myers Squibb (United States).
12 Oncology, Johns Hopkins University School of Medicine iborrell@jhmi.edu.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Al-Sawaf O, et al.
Journal of Clinical Oncology
November 2021
Authors and Affiliates
Othman Al-Sawaf, MD1,2,3; Can Zhang, PhD1; Tong Lu, PhD4; Michael Z. Liao, PhD4; Anesh Panchal, MSc5; Sandra Robrecht, PhD1; Travers Ching, PhD6; Maneesh Tandon, MBChB5; Anna-Maria Fink, MD1; Eugen Tausch, MD7; Christof Schneider, MD7;
Matthias Ritgen, MD8; Sebastian Bottcher, MD ¨ 9; Karl-Anton Kreuzer, MD1; Brenda Chyla, PhD10; Dale Miles, PhD4; Clemens-Martin Wendtner, MD11; Barbara Eichhorst, MD1; Stephan Stilgenbauer, MD7,12; Yanwen Jiang, PhD4; Michael Hallek, MD1; and Kirsten Fischer, MD1
1University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Germany 2The Francis Crick Institute, London, United Kingdom 3UCL Cancer Institute, University College London, London, United Kingdom 4Genentech, San Francisco, CA 5Roche Products Ltd, Welwyn Garden City, United Kingdom 6Adaptive Biotechnologies Corp, Seattle, WA 7
Department of Internal Medicine III, Ulm University, Ulm, Germany 8Department II of Internal Medicine, University of Schleswig- Holstein, Kiel, Germany 9Clinic III, Special Hematology Laboratory, Rostock University Medical School, Rostock, Germany 10AbbVie Inc, Chicago, IL 11Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany 12Department of Internal Medicine I, Saarland University Medical Center, Homburg, Germany